CDK4 and Miyoshi myopathy: Although pan-Cdk inhibitors have proven their anti-myeloma activity, selective Cdk4/6 inhibitors seem to be more attractive agents due to the important role of Cdk4/6 in regulating MM cell cycle progression and the toxic effects observed when targeting other Cdks, such as myelosuppression and enteropathy [103].